Research Reference
Noopept
Synthetic dipeptide cognitive enhancer
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
Noopept is a synthetic dipeptide cognitive enhancer studied for nootropic effects. It is not FDA approved in the US.
Reconstitution
Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is a synthetic nootropic dipeptide developed in the Russian Federation and registered there. It is taken as an oral tablet or sublingual powder — there is no injection and no reconstitution. It is not FDA-approved in the United States.
No compounded or lyophilized injectable form is established. Compounded "research" forms sold online are not FDA-approved.
Cycling Protocol
Studied protocols describe noopept taken orally (10 mg) 1–2 times daily for 1–3 months, sometimes followed by an off period. No standardized long-term cycle is established; noopept is not FDA-approved and durations are community extrapolation.
Routes of Administration
Oral / sublingual (established route): Taken as a tablet or sublingual powder by mouth. This is the route used in the published studies.
No subcutaneous, intranasal, or intravenous route is established. Compounded injectable forms are not FDA-approved.
Stacking Protocols
| Stack | Components | Purpose | | --- | --- | --- | | Nootropic Stack | Noopept + choline source / racetam | Combined cognitive support (community) | | Anxiolytic Stack | Noopept + Selank / Semax | Combined CIS-region nootropic (community) |
Stacking combinations are community extrapolation. Noopept is not FDA-approved.
Side Effects & Safety
- Headache — occasionally reported
- Irritability, fatigue — occasionally reported
- Generally described as well-tolerated in the published CIS-region literature at studied doses
- No large US safety database — the compound is not FDA-approved and Western safety data is limited
Noopept is not FDA-approved in the United States. It is registered in some other countries. Compounded forms are not FDA-approved.
Research Basis
Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is a synthetic nootropic dipeptide, developed in the Russian Federation as a piracetam analog with higher potency.
Mechanism: Described as increasing brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), modulating acetylcholine and glutamate signaling, and providing neuroprotective and anxiolytic effects.
Clinical evidence: Published CIS-region studies describe cognitive and anxiolytic benefits in cognitive impairment and post-stroke contexts, typically as oral 10 mg dosing. Not FDA-approved in the US; Western trial data is limited.
Not FDA-approved in the US. Compounded forms are sold for research purposes only.